Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Revised Protocol 07 to Protocol CA225006 - A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Carcinoma

Trial Profile

Revised Protocol 07 to Protocol CA225006 - A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Cetuximab (Primary) ; Irinotecan
  • Indications Carcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms EPIC
  • Sponsors ImClone Systems
  • Most Recent Events

    • 06 Jun 2008 EMEA extended MAA treatment inclusions to include use as a single agent.
    • 07 May 2008 Results have been published.
    • 08 Jan 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top